$63.85
2.68% today
Nasdaq, Apr 01, 06:21 pm CET
ISIN
US03940C1009
Symbol
ACLX
Sector
Industry

Arcellx Stock price

$65.60
+0.78 1.20% 1M
-17.91 21.45% 6M
-11.09 14.46% YTD
-1.38 2.06% 1Y
+51.58 367.90% 3Y
+50.60 337.33% 5Y
+50.60 337.33% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-2.36 3.47%
ISIN
US03940C1009
Symbol
ACLX
Sector
Industry

Key metrics

Market capitalization $3.60b
Enterprise Value $3.07b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 28.45
P/S ratio (TTM) P/S ratio 33.39
P/B ratio (TTM) P/B ratio 7.83
Revenue growth (TTM) Revenue growth -2.16%
Revenue (TTM) Revenue $107.94m
EBIT (operating result TTM) EBIT $-137.57m
Free Cash Flow (TTM) Free Cash Flow $-96.90m
Cash position $587.58m
EPS (TTM) EPS $-1.99
P/E forward negative
P/S forward 42.81
EV/Sales forward 36.47
Short interest 14.65%
Show more

Is Arcellx a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Arcellx Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Arcellx forecast:

17x Buy
100%

Analyst Opinions

17 Analysts have issued a Arcellx forecast:

Buy
100%

Financial data from Arcellx

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
108 108
2% 2%
100%
- Direct Costs 5.19 5.19
99% 99%
5%
103 103
5% 5%
95%
- Selling and Administrative Expenses 78 78
28% 28%
72%
- Research and Development Expense 157 157
17% 17%
146%
-132 -132
52% 52%
-123%
- Depreciation and Amortization 5.19 5.19
99% 99%
5%
EBIT (Operating Income) EBIT -138 -138
53% 53%
-127%
Net Profit -107 -107
52% 52%
-99%

In millions USD.

Don't miss a Thing! We will send you all news about Arcellx directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcellx Stock News

Neutral
Business Wire
12 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decade...
Neutral
GlobeNewsWire
14 days ago
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
Positive
Seeking Alpha
15 days ago
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
More Arcellx News

Company Profile

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Rami Elghandour
Employees 163
Founded 2014
Website www.arcellx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today